The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical Issues for Biochemical Markers of Acute Coronary Syndromes
Open accessAbstract
I. OVERVIEW OF ANALYTICAL ISSUES FOR ACUTE CORONARY SYNDROME (ACS) BIOMARKERS…548 A. Analytical Issues: Background…548 II. ANALYTICAL BIOMARKER ISSUES…548 A. Cardiac Troponin Specifications…548 B. Cardiac Biomarker Turnaround…549 C. Biomarkers No Longer Recommended for Use in the Context of ACS…549 D. Determining Biomarker Decision Cutoff Characteristics for ACS…549 E. European Society of Cardiology (ESC)/American College of Cardiology (ACC) Recommendations…550 III. REFERENCES…550 In 1999, the National Academy of Clinical Biochemistry (NACB)1 published the first standards of laboratory practice addressing analytical and clinical recommendations for use of cardiac markers in coronary artery diseases (1). The objectives were to recommend the appropriate implementation and utilization of cardiac biomarkers, specifically for cardiac troponin (cTn), which had just gained US Food and Drug Administration (FDA) clearance as a cardiac biomarker to aid in the diagnosis of acute myocardial infarction (AMI). In 2001, the IFCC Committee on Standardization of Markers of Cardiac Damage (C-SMCD) recommended quality specifications for analytical and preanalytical factors for cTn assays (2). The objectives were intended for use by the manufacturers of commercial assays and by clinical laboratories that use cTn assays. The overall goal was to establish uniform criteria so that all cTn assays could objectively be evaluated for their analytical qualities and clinical performance. These general principles can also be applied to creatine kinase MB (CK-MB) mass and myoglobin assays by use of the analytical recommendations in this document. In this report, we provide the background for establishing updated practice guidelines with recommendations addressing analytical issues for cardiac biomarkers based on 8 years of evidence-based medical and scientific observations since the publication of the initial recommendations (1). ALL CLASS I Reference decision-limits should be established for each cardiac biomarker based on a population of normal, healthy individuals without a known history of heart disease (reference population). For cardiac troponin I (cTnI) and T (cTnT), as well as for CK-MB mass, the 99th percentile of the reference population should be the decision-limit for myocardial injury. The Clinical Laboratory Standards Institute (CLSI; formerly NCCLS) recommends a minimum of 120 individuals per group of healthy individuals for appropriate statistical determination of a normal reference limit cutoff. Sex-specific reference limits should be used in clinical practice for CK-MB mass. For myoglobin, the 97.5th percentile (with sex-specific reference limits) should be the decision-limit for myocardial injury (Level of Evidence: B). One decision-limit, the 99th percentile, is recommended as the optimum cutoff for cTnI, cTnT, and CK-MB mass. ACS patients with cTnI and cTnT results above the decision-limit should be labeled as having myocardial injury and a high-risk profile (Level of Evidence: B). Assays for cardiac biomarkers should strive for a total imprecision (%CV) of ≤10% at the 99th percentile reference limit. Before introduction into clinical practice, cardiac biomarker assays must be characterized with respect to potential interferences, including rheumatoid factors, human anti-mouse antibodies, and heterophile antibodies. Preanalytical and analytical assay characteristics should include biomarker stability (over time and across temperature ranges) for each acceptable specimen type used in clinical practice and identification of antibody/epitope recognition sites for each biomarker. Analytical and preanalytical specifications developed by professional groups such as the IFCC should be followed (Level of Evidence: C). Serum, plasma, and anticoagulated whole blood are acceptable specimens for the analysis of cardiac biomarkers. Choice of specimen must be based on sufficient evidence and the known characteristics of individual biomarker assays (Level of Evidence: C). First, in the context of cTn, the epitopes recognized by the antibodies must be delineated. Epitopes located on the stable part of the cTnI molecule should be a priority. Specific relative responses need to be described for the following cTnI forms: free cTnI, the I-C binary complex, the T-I-C ternary complex, and oxidized, reduced, and phosphorylated isoforms of the 3 cTnI forms. The effects of different anticoagulants on binding of cTnI also need to be addressed. Second, the source of material used to calibrate cTn assays, specifically for cTnI, should be reported. A cTnI standardization subcommittee of the AACC in collaboration with the NIST has developed a primary reference material (SRM #2921) (3). Although this material demonstrated commutability with only 50% of current cTn assays, it will be of use in harmonizing cTnI concentrations across different assays (4)(5). At present, it appears that the only way to achieve complete standardization for cTnI would b
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antman, E., Bassand, J.-P., Klein, W., Ohman, M., Lopez Sendon, J. L., Rydén, L., Simoons, M., & Tendera, M. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00804-4 · Cited by 4,821
Braunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,487
Plasma brain natriuretic peptide concentration: impact of age and gender
Redfield, M. M., Rodeheffer, R. J., Jacobsen, S. J., Mahoney, D. W., Bailey, K. R., & Burnett, J. C. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02059-4 · Cited by 1,138
Committee Members, Braunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D., Kupersmith, J., et al. (2002) · Circulation · doi:10.1161/01.cir.0000037106.76139.53 · Cited by 845
Luepker, R. V., Apple, F. S., Christenson, R. H., Crow, R. S., Fortmann, S. P., Goff, D., Goldberg, R. J., Hand, M. M., Jaffe, A. S., Julian, D. G., et al. (2003) · Circulation · doi:10.1161/01.cir.0000100560.46946.ea · Cited by 810
Self-citationWu, A. H., Apple, F. S., Gibler, W. B., Jesse, R. L., Warshaw, M. M., & Valdes, R. (1999) · Clinical Chemistry · doi:10.1093/clinchem/45.7.1104 · Cited by 662
Self-citationIt’s Time for a Change to a Troponin Standard
Jaffe, A. S., Ravkilde, J., Roberts, R., Naslund, U., Apple, F. S., Galvani, M., & Katus, H. (2000) · Circulation · doi:10.1161/01.cir.102.11.1216 · Cited by 643
Self-citationBiomarkers in Acute Cardiac Disease
Jaffe, A. S., Babuin, L., & Apple, F. S. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.02.056 · Cited by 639
Self-citationApple, F. S., Wu, A. H. B., & Jaffe, A. S. (2002) · American Heart Journal · doi:10.1067/mhj.2002.124048 · Cited by 397
Self-citationEvaluation of Imprecision for Cardiac Troponin Assays at Low-Range Concentrations
Panteghini, M., Pagani, F., Yeo, K.-T. J., Apple, F. S., Christenson, R. H., Dati, F., Mair, J., Ravkilde, J., Wu, A. H. B., & the Committee on Standardization of Markers of Cardiac Damage of the IFCC (2004) · Clinical Chemistry · doi:10.1373/clinchem.2003.026815 · Cited by 368
Self-citationApple, F. S., Quist, H. E., Doyle, P. J., Otto, A. P., & Murakami, M. M. (2003) · Clinical Chemistry · doi:10.1373/49.8.1331 · Cited by 322
Self-citationWu, A. H. B., Smith, A. M., Wieczorek, S. J., Mather, J. F., Duncan, B. H., White, C. M., McGill, C. C., Katten, D. M., & Heller, G. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00741-0 · Cited by 260
Self-citationEvidence for Functional Heterogeneity of Circulating B-Type Natriuretic Peptide
Liang, F., O’Rear, J., Schellenberger, U., Tai, L., Lasecki, M., Schreiner, G. F., Apple, F. S., Maisel, A. S., Pollitt, N. S., & Protter, A. A. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.10.063 · Cited by 254
Self-citationMaisel, A. S., Clopton, P., Krishnaswamy, P., Nowak, R. M., McCord, J., Hollander, J. E., Duc, P., Omland, T., Storrow, A. B., Abraham, W. T., et al. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.01.013 · Cited by 250
Self-citationBruins, S., Fokkema, M. R., Römer, J. W. P., DeJongste, M. J. L., van der Dijs, F. P. L., van den Ouweland, J. M. W., & Muskiet, F. A. J. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.038752 · Cited by 221
Associations Among Androgens, Estrogens, and Natriuretic Peptides in Young Women
Chang, A. Y., Abdullah, S. M., Jain, T., Stanek, H. G., Das, S. R., McGuire, D. K., Auchus, R. J., & de Lemos, J. A. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.10.040 · Cited by 189
Wu, A. H. B. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.08.021 · Cited by 170
Self-citationApple, F. S., Parvin, C. A., Buechler, K. F., Christenson, R. H., Wu, A. H. B., & Jaffe, A. S. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2005.052886 · Cited by 135
Self-citationStandardization of Cardiac Troponin I Assays: Round Robin of Ten Candidate Reference Materials
Christenson, R. H., Duh, S., Apple, F. S., Bodor, G. S., Bunk, D. M., Dalluge, J. J., Panteghini, M., Potter, J. D., Welch, M. J., Wu, A. H. B., et al. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.3.431 · Cited by 111
Self-citationChristenson, R. H., Duh, S. H., Apple, F. S., Bodor, G. S., Bunk, D. M., Panteghini, M., Welch, M. J., Wu, A. H. B., & Kahn, S. E. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2006.068437 · Cited by 92
Self-citationApple, F. S., Chung, A., Kogut, M. E., Bubany, S., & Murakami, M. M. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2006.02.011 · Cited by 75
Self-citationPeter, J. V. S., Hartley, G. G., Murakami, M. M., & Apple, F. S. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2005.062562 · Cited by 72
Self-citationNewby, L. K., Alpert, J. S., Ohman, E. M., Thygesen, K. A., & Califf, R. M. (2002) · American Heart Journal · doi:10.1067/mhj.2002.129778 · Cited by 62
Self-citationStandardization of Cardiac Troponin I Measurements: The Way Forward?
Panteghini, M. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2005.054551 · Cited by 40
Self-citationHermann-Arnhof, K. M., Hanusch‐Enserer, U., Kaestenbauer, T., Publig, T., Dunky, A., Rosén, H., Prager, R., & Köller, U. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.035923 · Cited by 35
Cited by
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Self-citationAmsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000134 · Cited by 1,059
Self-citationAnalytical Characteristics of High-Sensitivity Cardiac Troponin Assays
Apple, F. S., Collinson, P. O., & for the IFCC Task Force on Clinical Applications of Cardiac Biomarkers (2012) · Clinical Chemistry · doi:10.1373/clinchem.2011.165795 · Cited by 861
Self-citation2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain
Gulati, M., Levy, P. D., Mukherjee, D., Amsterdam, E., Bhatt, D. L., Birtcher, K. K., Blankstein, R., Boyd, J., Bullock-Palmer, R. P., Conejo, T., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.053 · Cited by 824
Self-citationHow to use high-sensitivity cardiac troponins in acute cardiac care
Thygesen, K., Mair, J., Giannitsis, E., Mueller, C., Lindahl, B., Blankenberg, S., Huber, K., Plebani, M., Biasucci, L. M., Tubaro, M., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs154 · Cited by 784
Self-citation
Metadata
- Authors
- NACB WRITING GROUP MEMBERS, Apple, F. S., Jesse, R. L., Newby, L. K., Wu, A. H. B., Christenson, R. H., NACB COMMITTEE MEMBERS, Christenson, R. H., Apple, F. S., Cannon, C. P., Francis, G., Jesse, R., Morrow, D. A., Newby, L. K., Ravkilde, J., Storrow, A. B., Tang, W., Wu, A. H. B., IFCC COMMITTEE ON STANDARDIZATION OF MARKERS OF CARDIAC DAMAGE (C-SMCD) MEMBERS, Apple, F. S., Christenson, R. H., Jaffe, A. S., Mair, J., Ordonez-Llanos, J., Pagani, F., Panteghini, M., Tate, J., & Wu, A. H. B.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-04-01
- Volume
- 53
- Issue
- 4
- Pages
- 547-551
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2138210015
- Cited by
- 258
- References
- 25
- FWCI
- 16.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.